Vivek Subbiah: We need to challenge Standard-of-care Paradigms in the Precision Oncology era

Vivek Subbiah shared a post on LinkedIn:

“Such a delight to deliver a lecture and join an amazing panel discussion on Rare Cancer, Precision Medicine and how do we offer cutting edge personalized treatments and clinical trials for all patients with rare cancers everywhere.

“2024 Rare Cancer Symposium, Indianapolis, IN”

The time is now. We need to challenge Standard-of-care Paradigms in the Precision Oncology era.

Together we can all Eradicate Cancer

Thanks to Dr. Sumeet Bhatia and Dr. Ruemu Birhiray for the invite & organizing the meeting.

Incredible speaker line up .

Read about this idea in our paper published at Cell Press journal Trends in Cancer.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.